
AGO Breast Committee recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2026
OncologiaResumo original em inglês
O que aconteceu
The German Guideline Committee (AGO: Working Group on Gynecologic Cancers) updated its yearly recommendations on the diagnosis and treatment of breast cancer in March 2026. Chapters on oncological and oncoplastic-reconstructive surgery are coordinated with the Working Group for Plastic, Aesthetic, and Reconstructive Surgery in Gynecology (AWOgyn). The most important changes include the ommission of sentinel lymph node biopsy (SLNB) and preffered axillary staging in patients with node-positive breast cancer undergoing neoadjuvant chemotherapy (NACT). Targeted axillary dissection (TAD) is endorsed as the method of choice [AGO ++] in patients converting from cN + to ycN0 status, and other de-escalated techniques (SLNB, target lymph node biopsy [TLNB]) are also possible options [AGO +]. Following NACT, ALND is indicated only when macrometastatic disease is detected in the sentinel and/or in the target lymph node.
Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.
O estudo original
AGO Breast Committee recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2026
Maggie Banys-Paluchowski, Christine Solbach, Thorsten Kühn, Volkmar Müller, Nina Ditsch, Tanja Fehm, Ute-Susann Albert, Rupert Bartsch, Ingo Bauerfeind, Jens-Uwe Blohmer et al.
Descritores MeSH
- Breast Neoplasms
- Female
- Humans
- Lymph Node Excision
- Lymph Nodes
- Lymphatic Metastasis
- Neoplasm Staging
- Neoadjuvant Therapy
- Axilla
- Sentinel Lymph Node Biopsy